Updates
** Shares of medical device maker Abbott Laboratories ABT.N fall 7.3% to $122.11 premarket
** Abbott forecasts Q3 adj profit between $1.28 and $1.32 per share vs analysts' average estimate of $1.34 per share, according to data compiled by LSEG
** Company posts Q2 profit of $1.26 per share compared with analysts' estimate of $1.25 per share
** Reports Q2 revenue of $11.1 billion in line with expectations
** Its medical device business reports sales of $5.37 billion, above estimates of $5.24 billion
** Abbott expects headwind of around $700 million on 2025 sales growth in diagnostics
** RBC Capital Markets says it is disappointed with the 2025 outlook, but "believe that 7.5% year on year underlying growth with double-digit EPS growth for the business in Q2 is notable off of its large revenue base with impressive ongoing strength in diabetes"
** Leerink Partners sees reasons "to be encouraged with its MedTech segment delivering better-than-expected growth with broad-based strength during the quarter"
** Including session's moves, stock up 11.5% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.